Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.
about
The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway.STAT inhibitors for cancer therapy.A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis.A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.Therapeutic modulators of STAT signalling for human diseasesIdentification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies.Progress towards the development of SH2 domain inhibitors.Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors.Efficient synthesis of conformationally constrained, amino-triazoloazepinone-containing di- and tripeptides via a one-pot Ugi-Huisgen tandem reaction.Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules.Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma.Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo.A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells.Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer AgentsDistinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.Structure-Activity Studies of Phosphopeptidomimetic Prodrugs Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3 (Stat3).Signal transducer and activator of transcription 3 inhibitors: a patent review.Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.Targeting the tumor microenvironment by immunotherapy: part 2.Could signal transducer and activator of transcription 3 be a therapeutic target in obesity-related gastrointestinal malignancy?Current and future intratumoral targeted treatment for pancreatic cancer.A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformationA STAT inhibitor patent review: progress since 2011.Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer.Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 proteinPotent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.The crossroads of breast cancer progression: insights into the modulation of major signaling pathways.Linker Variation and Structure-Activity Relationship Analyses of Carboxylic Acid-based Small Molecule STAT3 Inhibitors.The STAT3 Target Gene TNFRSF1A Modulates the NF-κB Pathway in Breast Cancer Cells.
P2860
Q26861758-272ED770-2B99-40D2-B9BE-942EDCC26B6AQ30303147-43CCFE44-460B-4A1D-9B7B-091444F5F94AQ33644206-DFEF581B-2061-4A56-ACB2-A7B8051D0C83Q33661939-EDC8E5A4-2295-4CB8-BF9F-DD85E3F7B91AQ33679564-6400C9C2-ED09-4EDD-86DF-58DDF50CDCFDQ33684732-D8CB211E-0FA0-4F0F-824F-CA6EF5089C70Q34492859-AA5413D8-F506-4562-8BB0-962917CB3CC1Q34581878-56914981-915F-4575-83DD-A79BBB642644Q35000997-51D2F9FB-38EB-4CDD-806D-8D1D2D832601Q35223514-F542DDCF-CAF6-438E-8A43-05795F0F4877Q35329489-860CEAA7-805A-4D91-A154-B4F1CCDBA06EQ35761986-CF9FD0BF-F69D-4B28-B94E-296FC81D98A4Q35869426-64DB1FF7-A978-4010-BAAB-6F78910E230FQ36066234-F7466C0A-B6C7-41C0-AD9E-696F5995026AQ36385313-24A0A7A0-1DB9-45A4-ACE2-088BA72C07F1Q36389325-88C0CC09-8FAC-4F6D-BE4E-4BCD470B5452Q36641981-FE02F6B8-08F7-4EA9-B8C2-9E7561C7EF9EQ37068166-F6C9889F-329A-4F36-8F91-2B3AE34E4A41Q37113973-41AF849E-4C25-46C4-9BBF-C30732D40441Q37683068-DAD6A051-1F87-4A5D-B60A-D6B088674055Q37813134-BC83ED33-CAB2-4737-8CB1-75E5B3DBE95BQ37869903-F2402069-CE92-4B46-B70F-F30559ECFC44Q37952796-3D9EE4D4-FC48-496B-AD7E-4E98A76C274DQ38155819-ED17A4EA-77B6-4F6F-B220-D98D2D149BD8Q38261961-9BAFF255-4FDC-4556-B3A6-F8A5712CCA0AQ38318481-01615B87-FD56-4D24-9716-F31754FBD1D4Q38591166-E99D39B7-A5E8-4E23-818F-0FFC15AC71BBQ39096364-843F01F7-0D24-4682-A0A1-92CF5A45EE06Q39159381-F2D0095E-1C6F-4CAF-A03A-D71AA9DD69E9Q39610489-853B05F9-0D74-4099-BC66-230CE81CB4E3Q39778880-7180B0DD-0CC1-4C44-A1F8-15D23A56EDCBQ47133172-40C317E9-8F18-45D0-9CDD-C2C9D6B2812EQ47167746-522596B2-45AD-425B-9F8C-1E575C93F141Q52655071-486FF79D-5AA2-4E1B-8380-3BD51246F9D6Q55278638-7183FCD8-2EAD-4802-8AA0-277DECA89EF4
P2860
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.
@en
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.
@nl
type
label
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.
@en
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.
@nl
prefLabel
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.
@en
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.
@nl
P2093
P2860
P356
P1476
Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors
@en
P2093
Cindy Gomez
Jian Zhang
Jianyong Chen
Longchuan Bai
Zaneta Nikolovska-Coleska
P2860
P356
10.1021/ML100010J
P577
2010-05-01T00:00:00Z